Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Average Recommendation of "Buy" by Brokerages

Key Points

• Structure Therapeutics Inc. (NASDAQ:GPCR) has received a consensus recommendation of "Buy" from seven investment analysts in the last year, with an average target price of $76.17.
• Hedge funds have recently increased their positions in Structure Therapeutics, with notable boosts including a 1,448.2% increase by National Bank of Canada FI and a 673.4% increase by Tower Research Capital LLC.
• Despite its favorable analyst ratings, Structure Therapeutics' stock has seen a 1.8% decline, currently trading at $17.94 after reporting a quarterly earnings miss of ($0.27) EPS.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) has earned an average recommendation of "Buy" from the seven research firms that are covering the stock, MarketBeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have covered the stock in the last year is $76.17.

A number of research firms have weighed in on GPCR. JMP Securities reiterated a "market outperform" rating and issued a $89.00 target price on shares of Structure Therapeutics in a research note on Monday, June 23rd. Citigroup assumed coverage on Structure Therapeutics in a research note on Friday, May 2nd. They set a "buy" rating and a $60.00 price target on the stock. HC Wainwright cut their price target on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a research note on Monday, May 12th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, June 23rd.

Institutional Investors Weigh In On Structure Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Deep Track Capital LP lifted its holdings in shares of Structure Therapeutics by 129.4% during the fourth quarter. Deep Track Capital LP now owns 2,800,000 shares of the company's stock worth $75,936,000 after purchasing an additional 1,579,492 shares during the period. Vestal Point Capital LP lifted its holdings in shares of Structure Therapeutics by 50.0% during the fourth quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company's stock worth $46,782,000 after purchasing an additional 575,000 shares during the period. Boxer Capital Management LLC acquired a new stake in shares of Structure Therapeutics during the fourth quarter worth about $13,560,000. Pacific Heights Asset Management LLC acquired a new stake in shares of Structure Therapeutics during the second quarter worth about $9,540,000. Finally, Marshall Wace LLP lifted its holdings in shares of Structure Therapeutics by 339.6% during the fourth quarter. Marshall Wace LLP now owns 583,207 shares of the company's stock worth $15,817,000 after purchasing an additional 450,531 shares during the period. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Trading Up 0.5%

NASDAQ:GPCR traded up $0.09 during midday trading on Monday, hitting $17.92. 206,981 shares of the company traded hands, compared to its average volume of 856,275. The firm's fifty day moving average is $20.71 and its 200-day moving average is $22.33. Structure Therapeutics has a 12-month low of $13.22 and a 12-month high of $45.37. The firm has a market capitalization of $1.03 billion, a P/E ratio of -20.49 and a beta of -1.87.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). On average, research analysts expect that Structure Therapeutics will post -0.82 EPS for the current fiscal year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.